Company: MIRM
Filing Date: 2025-11-04
Form Type: SCHEDULE 13D/A
Source: 0001231919-25-000420
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: SCHEDULE 13D/A
Chunk 0
---
 % |
| 14                                                                 |                                                                                   PN |

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P. The percentage listed in row 13 is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.

| SCHEDULE 13D |

| CUSIP No. | 604749101 |

| 1                                                                  |                                                                       FHMLSP, L.L.C. |
| 2                                                                  |                                                                                -a)(b |
| 3                                                                  |                                                                         SEC use only |
| 4                                                                  |                                                                                   AF |
| 5                                                                  |  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) |
| 6                                                                  |                                                                             DELAWARE |
| Number of Shares Beneficially Owned by Each Reporting Person With: |                                                                   7           0.00   
                                                                   8   2,514,947.00   
                                                                   9           0.00   
                                                                     10  2,514,947.00 |
| 11                                                                 |                                                                         2,514,947.00 |
| 12                                                                 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| 13                                                                 |                                                                                5.0 % |
| 14                                                                 |                                                                                   OO |

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P. The percentage listed in row 13 is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.

| SCHEDULE 13D |

| CUSIP No. | 604749101 |

| 1                                                                  |                                                       Frazier Life Sciences XI, L.P.